Table 1.

Proportion of patients with complete or partial clearance and median reduction in number of lesions at day 57 (pooled analyses)

Face or scalp	Ingenol mebutate, 0.015% (n = 277)	Vehicle (n = 270)
Complete clearance rate	42.2	3.7
Partial clearance rate (≥75% of lesions)	63.9	7.4
Median reduction in number of lesions, %*	83	0
Trunk or extremities	Ingenol mebutate, 0.05% (n = 226)	Vehicle (n = 232)
Complete clearance rate	34.1	4.7
Partial clearance rate (≥75% of lesions)	49.1	6.9
Median reduction in number of lesions, %†	75	0

Notes:

^*n = 273, ingenol mebutate; n = 269, vehicle;

^†n = 220, ingenol mebutate; n = 229, vehicle.

Copyright © 2012. Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society from Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010–1019.⁵⁷